SynthesisAdvances in therapy2023

Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review.

Jiejin Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.